BioStock: PHIs CEO eyes new business opportunities

March 31, 2022
Language flag

In 2021, PHI entered into a partnership with the US-based RegenMed Development Organization with the goal of establishing the company’s HoloMonitor technology as the standard quality control equipment in the growing field of regenerative medicine. The company has also chartered a new course when it comes to marketing strategy, with a sharp increase in sales over the last 4 quarters as a result. BioStock contacted CEO Peter Egelberg to find out more about the rights issue of just over 72 million SEK that is currently underway, and his vision for the future.

Read the full interview with Peter Egelberg on biostock.se.

Latest News

Peter Egelberg CEO PHI

Founder and board member subscribes for shares in the ongoing rights issue

Peter Egelberg, founder and Board member of Phase Holographic Imaging PHI AB has notified the Company that he, together with closely related parties, follows Altium SA’s lead by subscribing for shares in the Company’s ongoing fully secured rights issue. The subscription amounts to approximately 300 TSEK.
AndersMansson-web

PHI at Aktieportföljen Live, BioStock and Financial Stockholm

The subscription period in PHI AB’s fully secured rights issue, totalling SEK 64.3 million, is ongoing until 20 December 2024. The Company’s CEO, Anders Månsson, has during the last couple of weeks presented the Company and its future plans. For links to the presentations and the podcast, see below.

Notice of Annual General Meeting in Phase Holographic Imaging PHI AB (publ) 8 January 2025

The shareholders of Phase Holographic Imaging PHI AB (publ), (“the Company”), reg.no. 556542-7811, are hereby invited to attend the general meeting on 8 January 2025 at 15.00 at the Company´s office at Skiffervägen 48 in Lund.
See All News